Novavax Inc mentioned on Friday it had began engaged on a model of its COVID-19 vaccine to focus on the variant detected in South Africa and would have the shot prepared for testing and manufacturing within the subsequent few weeks.
The corporate’s COVID-19 shot incorporates an precise model of the virus’ spike protein that can’t trigger illness however can set off the immune system. The vaccine developer mentioned it had began growing a spike protein particularly based mostly on the identified genetic sequence of the variant, B.1.1.529.
“The preliminary work will take just a few weeks,” an organization spokesperson mentioned. Shares of the corporate closed up practically 9% on Friday.
Learn extra:
Canada clamps down on Omicron COVID-19 variant. Consultants say it’s possible ‘already right here’
Novavax’s vaccine obtained its first emergency use approval earlier this month in Indonesia adopted by the Philippines.
The corporate has mentioned it’s on monitor to file for U.S. approval by the top of the yr. It has additionally filed for approvals with the European Medicines Company in addition to in Canada.
Different vaccine builders, together with Germany’s BioNTech SE and Johnson & Johnson, have mentioned they’re testing the effectiveness of their pictures towards the brand new variant, which is known as Omicron by the World Well being Organisation.
Inovio Prescribed drugs Inc mentioned it had begun testing its vaccine candidate, INO-4800, to judge its effectiveness towards the brand new variant. The corporate expects the testing to take about two weeks.
Learn extra:
Explainer: What is that this new COVID-19 variant rising in South Africa?
Inovio additionally mentioned it was concurrently designing a brand new vaccine candidate that particularly focused Omicron.
“Greatest case situation, INO-4800 … can be utterly resilient towards omicron, but when that’s not the case then we could have a newly designed vaccine able to go if want be,” mentioned Kate Broderick, senior vice chairman of Inovio’s R&D division.
Earlier this month, Inovio resumed a late-stage trial of its vaccine in the US after 14 months on scientific maintain.
(Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Enhancing by Anil D’Silva)
View hyperlink »
